Evaluation of dexamethasone effects in COVID-19 treatment

Hamza Khalifa Ibrahim; Naeimah Ahmeed Ahseen; Tousief Irshad Ahmed; Nisreen Ahmeed Ahseen; Noor-Alhooda M Al-Awkally; Aejeeliyah Yousuf

doi:10.53730/ijhs.v6nS1.4799

Authors

Hamza Khalifa Ibrahim
hamzakhlifa2009@gmail.com
Department of Pharmacy Higher Institute of Medical Technology - Bani Waleed Bani Waleed, Libya
Naeimah Ahmeed Ahseen Faculty of Medicine Tripoli University- Libya
Tousief Irshad Ahmed Senior resident department of cl. Biochemistry SKIMS, Soura , Srinagar, J & K, India
Nisreen Ahmeed Ahseen Department of Pharmacy Higher Institute of Medical Technology - Bani Waleed Bani Waleed, Libya
Noor-Alhooda M Al-Awkally Medical Laboratory Department, Higher Institute of Science and Technology, Sulug
Aejeeliyah Yousuf Department of Laboratory Higher Institute of Medical Technology - Bani Waleed Bani Waleed, Libya

Keywords:

coronavirus, COVID-19, dexamethasone, treatment

Abstract

(COVID-19) Finding a cure for Corona virus sickness in 2019 will be a difficult task for researchers all over the globe, since it is associated with significant lung damage and the potential for multiple organ failure. To far, dexamethasone has shown substantial benefits in COVID-19, reducing mortality while improving recovery. There is a reduction in inflammation due to a reduction in inflammation-related immune responses and a decrease in cytokine production, which prevents COVID-19 from becoming more severe. Dexamethasone's significance in the treatment of COVID-19 is currently unproven. When it comes to combating this pandemic, COVID-19's pathophysiology and dexamethasone's efficacy are the deciding factors.

Downloads

Download data is not yet available.

References

Abraham, S. M., Lawrence, T., Kleiman, A., Warden, P., Medghalchi, M., Tuckermann, J., ... & Clark, A. R. (2006). Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. The Journal of experimental medicine, 203(8), 1883-1889.

Calabrese, F., Pezzuto, F., Fortarezza, F., Hofman, P., Kern, I., Panizo, A., ... & Lunardi, F. (2020). Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European Pulmonary Pathologists. Virchows archiv, 477(3), 359-372.

Corman, VM, Lienau, J., & Witzenrath, M. (2019). Corona viruses as a cause of respiratory infections. The Internist , 60 (11), 1136-1145.

Florindo, H. F., Kleiner, R., Vaskovich-Koubi, D., Acúrcio, R. C., Carreira, B., Yeini, E., ... & Satchi-Fainaro, R. (2020). Immune-mediated approaches against COVID-19. Nature nanotechnology, 15(8), 630-645.

Gyamfi-Bannerman, C., Thom, E. A., Blackwell, S. C., Tita, A. T., Reddy, U. M., Saade, G. R., ... & Jain, L. (2016). Antenatal betamethasone for women at risk for late preterm delivery. New England Journal of Medicine, 374(14), 1311-1320.

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., ... & Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet, 395(10223), 497-506. https://doi.org/10.1016/S0140-6736(20)30183-5

Ibrahim, H. K., Mohammed, A. A., & Omar, O. A. (2018). Effects of Antibiotics (Ciprofloxacin–Augmentin–Gentamicin–Norfloxacin–Ampicillin) which are used for Treatment of Urinary Tract Infections in Female Patients. V, Issue, 10.

Johnson, D. B., Lopez, M. J., & Kelley, B. (2018). Dexamethasone.

Khaliha, H., Saed, A., & Daw, S. (2020). Hydroxychloroquine And Dexamethasone Are Both Possible For Treatment Of Covid-19.

Kolias, A. G., Edlmann, E., Thelin, E. P., Bulters, D., Holton, P., Suttner, N., ... & Hutchinson, P. J. (2018). Dexamethasone for adult patients with a symptomatic chronic subdural haematoma (Dex-CSDH) trial: study protocol for a randomised controlled trial. Trials, 19(1), 1-14.

Ledford, H. (2020). Coronavirus breakthrough: dexamethasone is first drug shown to save lives. Nature, 582(7813), 469-470.

Liggins, G. C., & Howie, R. N. (1972). A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics, 50(4), 515-525.

Mahase, E. (2020). Covid-19: demand for dexamethasone surges as RECOVERY trial publishes preprint. BMJ: British Medical Journal (Online), 369.

Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020). COVID-19: consider cytokine storm syndromes and immunosuppression. The lancet, 395(10229), 1033-1034.

Momattin, H., Al-Ali, A. Y., & Al-Tawfiq, J. A. (2019). A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Travel medicine and infectious disease, 30, 9-18. https://doi.org/10.1016/j.tmaid.2019.06.012

Ogbru, O. (2020). Decadron (Dexamethasone): COVID-19 Coronavirus Drug. MedicineNet.

Rhen, T., & Cidlowski, J. A. (2005). Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. New England Journal of Medicine, 353(16), 1711-1723.

Sibila, O., Luna, C. M., Agusti, C., Baquero, S., Gando, S., Patrón, J. R., ... & Torres, A. (2008). Effects of glucocorticoids in ventilated piglets with severe pneumonia. European Respiratory Journal, 32(4), 1037-1046.

Siddiqi, H. K., & Mehra, M. R. (2020). COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal. The journal of heart and lung transplantation, 39(5), 405-407.

World Health Organization. (2019). World Health Organization model list of essential medicines: 21st list 2019 (No. WHO/MVP/EMP/IAU/2019.06). World Health Organization.

Yasir, M., Goyal, A., Bansal, P., & Sonthalia, S. (2018). Corticosteroid adverse effects.